ϸ°ûÄÚpHÖµ,intracellular pHÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Tϸ°û¿Ë¡ÐÔ,T cell clonalityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
HL-60/ADRϸ°û,HL-60/ADR cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢¹ÜÏà¹Øµ°°×ÖÊÀà/´úл,microtubule-associated proteins/metabolismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶þ¼Û½ðÊôÀë×ÓתÔËÌå1,divalent metal transporter 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
NF-¦ÊBÒÖÖÆ¼Á,NF-¦ÊB inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÑÖβ¡,REFRACTORY DISEASESÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Jurkatϸ°ûϵ,Jurkat cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ы¶¾ÒºÀà,Scorpion venomÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Í·¾±²¿Ö×Áö/·ÅÉäÁÆ·¨,Head and neck neoplasms/radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂËÅÝÊ÷ͻϸ°ûÈâÁö,follicular dendritic cell sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
P170,P 170Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´ó¿ÅÁ£ÁܰÍϸ°û,Large Granular LymphocyteÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÃâÒßĸϸ°ûÁܰͽᲡ,immunoblastic lymphadenopathyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÀÛ»ý¼ÁÁ¿,Accumulated DoseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DNAµç»¯Ñ§Ì½Õë,DNA electrochemical probeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Æ¢Ö×Áö/²¡Àíѧ,Splenic Neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Á¢Ì嶨ÏòÊÊÐηÅÁÆ,stereotactic radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»¯ÁÆÁÆÐ§,chemotherapeutic effectÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒìÁòÇèËá±½¼ºõ¥,phenylhexyl isothiocyanateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ùÒòsurvivin,Gene survivinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂËÅÝÐÍÁܰÍÁö,Follicular lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
TCR¦ÆÁ´,TCR ¦Æ chainÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±ÇÐÍ,nasal typeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
HL-60ϸ°ûÖê,HL-60 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö¸ººÉ,Tumor loadÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
賦µÀÁܰÍÁö,Gastrointestinal lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍâÖÜTϸ°û,Peripheral T-cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÒ×´Áܰ͹ÜÁö,cystic lymphangiomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼±ÐÔÁ£Ï¸°û°×Ѫ²¡,Acute myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶àÒ©ÄÍÒ©Äæ×ª,reversion of MDRÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼±ÐÔºì°×Ѫ²¡,acute erythroleukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È˼±ÐÔËèÐÔ°×Ѫ²¡,human acute myeloid leukaemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈýÑõ»¯¶þÉé(As2O3),arsenic trioxideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
cDNA΢¾ØÕó,cDNA microarrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
13q14ȱʧ,13q14 deletionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Rajiϸ°ûÖê,Raji cell linesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
KM3ϸ°û,KM3 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ĤÁªµ°°×¢ò,Annexin ¢òÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
EL4ϸ°û,EL4 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁܰÍϸ°ûÊä×¢,lymphocyte transfusionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
CA46ϸ°û,CA46 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ы¶¾¶àëÄÌáÈ¡Îï,Polypeptide extract from scorpion venom(PESV)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
V¦ÂÑǼÒ×å,V¦Â subfamilyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔçÓ×Á£Ï¸°û°×Ѫ²¡,promyelocytic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
LMP1»ùÒò,latent membrane protein 1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
STI571,STI 571Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¦Ã-·ÖÃÚøÒÖÖÆ¼Á,¦Ã-secretase inhibitorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈËÆêѪ»ùÖÊϸ°û,human umbilical cord blood stromal cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Áܰͽá×ªÒÆ°©,lymph node metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
MICM·ÖÐÍ,MICM classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶îÍâȾɫÌå,Extra chromosomeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ѪÇåLDH,serum LDHÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
FLT3/ITD»ùÒòÍ»±ä,FLT3/ITD mutationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶à·¢ÐÔ¹ÇËèÁöϸ°û,Multiple MyelomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐÞÊκËÜÕ,modified nucleosidesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô·¢ÐÔ¶ñÐÔÖ×Áö,Primary malignant tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Rb1»ùÒò,Rb1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´ó¼ÁÁ¿°¢ÌǰûÜÕ,High dose cytarabineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂÛÎÄ·ÖÎö,paper analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
"ÈýÃ÷ÖÎ"½á¹¹,sandwich structureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Æ¢Ö×Áö/Íâ¿ÆÑ§,Splenic Neoplasms/surgÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
KG-1aϸ°ûϵ,KG-1a cell linesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Æô¶¯×ÓÇø¼×»ù»¯,promoter methylationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûËữ,intracellular acidificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒøÐÓÒ¶¶àÌÇ,polysaccharides of ginkgo biloba leafÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÊÔÑéÆÀ¼Û,Experimental evaluationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»¯Ñ§È¾É«,chemical dyeingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÜÉú9ºÅȾɫÌå,derivative chromosome 9Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍêÈ«»º½â,complete remissionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ôм¤ËØÊÜÌåB»ùÒò,Progesterone receptor B geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼±ÐÔËèÐÔϸ°û°×Ѫ²¡,acute myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÊõÖбù¶³,frozen sectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ѫ¹ÜÄÚ´óBϸ°ûÁܰÍÁö,Intravascular large B-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼±±äÆÚ,blast crisisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
NotchÊÜÌå,Notch receptorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ñ¼°¶Ï¸°û,Littoral cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
9-˳ʽά¼×Ëá,9-cis-retinoic acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È˶ËÁ£Ã¸Äæ×ªÂ¼Ã¸(hTERT),human telomerase reverse transcriptase(hTERT)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÇËðº¦,bone damageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
CCAATÔöÇ¿×Ó½áºÏµ°°×,CCAAT/enhancer-binding proteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÆÏÌÑÌÇÉñ¾õ£°·ºÏø»ùÒò,glucosylceramide synthase geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÇËèÁö¹Ç²¡,Myeloma bone diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°×Ѫ²¡Ï¸°ûÖê,leukemia cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
RPMI8226ϸ°ûϵ,RPMI8226 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
MP·½°¸,MP regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
THP-1ϸ°ûÖê,THP-1 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
CA46ϸ°ûϵ,CA46 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
PML/RARaÈںϻùÒò,PML-RARa fusion geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚ²¿´®ÁªÖظ´,internal tandem duplicationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
СéÞ°·ÑÜÉúÎï,Berbamine derivativeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍâÖÜTϸ°ûÁܰÍÁö,Peripheral T-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Raji,Raji cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ëèϸ°û°×Ѫ²¡,Myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
PML»ùÒò,PML geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³£¹æÏ¸°ûÒÅ´«Ñ§,Conventional cytogeneticsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÇËè×ªÒÆ,Bone marrow metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÇÖÏ®ÐÔ·Ç»ôÆæ½ðÁܰÍÁö,Aggressive non-Hodgkin's lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°û¶¾Ò©Îï,cytotoxic drugsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½â¾ÈÖÎÁÆ,Salvage treatmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|